ITI Pharma and Healthcare Fund
NAV
₹19.74
as of 21 Aug 2026
ITI Pharma and Healthcare Fund is an open-ended Sectoral/ Thematic scheme from ITI Mutual Fund managing ₹263 crore (as of 31 Jul 2026). Its Direct-plan NAV is ₹19.74 as of 21 Aug 2026. The expense ratio is 0.95% a year. Managed by Rohan Korde. This page is factual data only — it carries no rating and no recommendation.
Key facts
- Expense ratio
- 0.95% / yr
- as of 30 Jun 2026
- Fund size
- ₹263 crore
- as of 31 Jul 2026
- Exit load
- 0.5%
- SIP available
- Yes
- Launched
- 11 Nov 2021
- ISIN
- INF00XX01BO9
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from NYVO’s own NAV data.
Rebased to 100data to 20 Aug 2026Benchmark: Nifty 500 Healthcare TRI
ITI Pharma and Healthcare Fund
₹198
+98% on ₹100 over 4.8 yrs
Sectoral/ Thematic average
₹212
+112% on ₹100 over 4.8 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | 8.39% | 6.78% | +1.61 |
| 6 months | 18.49% | 3.68% | +14.81 |
| 1 year | 12.32% | 6.07% | +6.25 |
| 3 years (CAGR) | 20.01% | 16.01% | +4.00 |
| 5 years (CAGR) | 15.41% | 15.20% | +0.21 |
Category average across 119 funds, as of 21 Aug 2026. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible — read that number first.
1-year holding periods
- Worst
- -9.1%
- Median
- 13.3%
- Best
- 61.1%
46 windows over the last 57 months, stepped monthly; 76% ended positive. Worst window began 1 Jan 2025. Windows overlap — this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 18.9%
- Median
- 21.4%
- Best
- 26.0%
22 windows over the last 57 months, stepped monthly; 100% ended positive. Worst window began 1 Feb 2023. Windows overlap — this is the range of past start dates, not a probability of anything.
Risk, measured
- Sharpe ratio (3Y)
- 0.83
- Sortino ratio (3Y)
- 1.37 vs category 1.55
- Standard deviation (3Y)
- 16.42%
- Beta (3Y)
- 0.99
- Alpha (3Y)
- -1.58%
Distance below its own peak
Every dip below 0 is the fund trading under a previous high — how deep and for how long is what a drawdown feels like.
Deepest fall
-16.1%
Right now
-1.3% below peak
Ahead of its benchmark in 39% of months (window: 3y, monthly) — benchmark: Nifty 500 Healthcare TRI, name shown only.
Where the money actually is
Equity
97.9%
Cash
2.1%
Whole-portfolio split, as of 31 Jul 2026.
What it owns
39 positions · top 10 = 57.4%
Market-cap mix
Large 36.5%Mid 39.9%Small 21.4%Other 2.1%
as of 31 Jul 2026
Holdings by sector
Healthcare(10 in top 10)93.9%
- Sun Pharmaceuticals Industries Ltd13.26%
- Divi's Laboratories Ltd7.97%
- Apollo Hospitals Enterprise Ltd6.05%
- Max Healthcare Institute Ltd Ordinary Shares5.05%
- Torrent Pharmaceuticals Ltd4.84%
- Cipla Ltd4.43%
- Dr Reddy's Laboratories Ltd4.41%
- Laurus Labs Ltd4.21%
- Aurobindo Pharma Ltd3.84%
- Mankind Pharma Ltd3.39%
- Basic Materials3.0%
- Industrials0.5%
- Financial Services0.5%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 31 Jul 2026. Portfolio turnover 63.9% vs category 37.3% a year.
The businesses it owns
- P/E (trailing)
- 43.6 vs category 25.8
- P/B
- 6.0 vs category 3.8
- Dividend yield
- 0.5% vs category 1.1%
- Net margin
- 15.1% vs category 15.4%
- Earnings growth
- 15.5%
- Avg market cap
- ₹88,486 crore
Money in, money out
- Net flow, 3 months
- +₹4 cr
as of 31 Jul 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of ITI Pharma and Healthcare Fund?
- ₹19.74 per unit as of 21 Aug 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of ITI Pharma and Healthcare Fund?
- 0.95% a year for the Direct plan, as of 30 Jun 2026.
- How large is ITI Pharma and Healthcare Fund?
- ₹263 crore under management as of 31 Jul 2026, in the Sectoral/ Thematic category.
- How risky is ITI Pharma and Healthcare Fund?
- Its SEBI Riskometer reading is "Very High Risk". One sector, one story. The most-launched shelf on the map, by far.
- What are the 5-year returns of ITI Pharma and Healthcare Fund?
- 15.41% a year over the last 5 years (Direct plan, CAGR), against a Sectoral/ Thematic average of 15.20%. Past returns do not predict future returns.
- What is the worst 3-year return of ITI Pharma and Healthcare Fund?
- 18.9% a year — the weakest of 22 overlapping 3-year holding periods, beginning 1 Feb 2023. The median was 21.4% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages ITI Pharma and Healthcare Fund?
- Rohan Korde, managing this fund for 4.4 years.
Where this fund sits
Its shelf, all funds
St · Sectoral / thematic →
One sector, one story. The most-launched shelf on the map, by far.
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund — growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Sectoral/ Thematic funds
- ICICI Prudential India Opportunities Fund₹38,299 crore
- ICICI Prudential Business Cycle Fund₹16,123 crore
- ITI Banking and Financial Services Fund₹386 crore
- ITI Bharat Consumption Fund₹370 crore
- LIC MF Banking and Financial Services Fund₹270 crore
- quant Teck Fund₹269 crore
- Mahindra Manulife Innovation Opportunities Fund₹236 crore
- SBI Equity Minimum Variance Fund₹215 crore
Data: NYVO research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (Nifty 500 Healthcare TRI) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.